Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 28, 2008

Brain and BioSilta to Develop Enzyme Expression and Discovery Technologies

  • Brain and BioSilta agreed to work together to advance tools for protein expression and enzyme discovery. The partnership will leverage BioSilta’s EnBase cell culture platform.

    Under the terms of the agreement, Brain gains access to EnBase, while BioSilta obtains access to application-relevant process developments.

    The goal is to optimize microwell plate-based high cell density protein expression and high-throughput enzyme discovery technologies. EnBase will be used to accelerate enzyme discovery and improve expression of enzymes.  The product is characterized by enzyme-based substrate delivery from a polymer layer to the cultivation medium for high-throughput screening with expression libraries and commercially relevant microbial host strains.

    “We enable customers to improve the yield and the quality of simple bacterial cultures,” according to Russell Golson, CEO of BioSilta. “You can obtain up to 50 times more bacteria and consequently higher amount of recombinant proteins in the same volume with our innovative EnBase products.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »